Cardiac imaging

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Retrieved on: 
Monday, February 26, 2024
Sengupta, HSCS, Rutgers University, Division, AI, Intelligence, Cardiac imaging, Education, Teaching, Echocardiography, University School, Editor-in-chief, ECG, American Medical Association, Society, Heart failure, Lung, TEDMED, European Society of Cardiology, Journal, FACC, MBBS, Publication, Holography, Research, Medical device

Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.

Key Points: 
  • Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
  • He served on the Board of Directors for the American Society of Echocardiography (ASE) and as the Chair of the ASE Telehealth and New Technology Taskforce.
  • In 2020, Dr. Sengupta was named a Richard Popp Excellence in Teaching Award recipient by the American Society of Echocardiography.
  • I look forward to helping HeartSciences further advance the field of AI in cardiology.”

Inteleos Announces 2024 Board of Directors

Retrieved on: 
Friday, February 9, 2024
University of Colorado Hospital, Health, UCHealth, State College, Pennsylvania, Vein, Associate, Cardiac imaging, Feinberg School of Medicine, Business, Education, Oregon Institute of Technology

ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, today announced its Board of Directors.

Key Points: 
  • ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, today announced its Board of Directors.
  • Inteleos' new Board is composed of a diverse mix of leaders with deep experience in global healthcare, technology, business and finance.
  • “We are very pleased to welcome six current Board Members - some to new roles - as well as our newest board members, a few of whom have served Inteleos’ councils for some time,” said Inteleos CEO Dale Cyr.
  • “This stellar group of professionals are dedicated to the advancement of global quality patient care, lifelong learning and to the latest technological advances in medicine and business.”
    The new Board will leverage its expertise to help Inteleos advance its mission to fuel the global health community to ensure equitable access to quality care.

Ziosoft Features Cardiac MR and CT Imaging Applications at Annual SCMR Conference

Retrieved on: 
Friday, January 26, 2024
Magnetic resonance, Society, Workflow, Business development, Cardiac imaging, UI, Marketing, Myopathy, Medical device

LONDON, Jan. 26, 2024 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer in 3D/4D AI medical visualization, will feature its unique REVROAS-enabled cardiac imaging program at the annual Society of Cardiology in Magnetic Resonance (SCMR) being held January 25 – 27, 2024 in London. Renowned for decades of expertise in Cardiac Imaging, with several thousand installations, the company has undertaken a transformative initiative to enhance user experience and streamline workflows through a revamped user interface.

Key Points: 
  • By leveraging this expertise in cardiac imaging, we have developed a unified cardiac imaging solution on a singular platform for seamless workflow, enabling medical professionals to focus on enhanced diagnostic precision.
  • "Our track record boasts substantial success in the field of cardiac imaging, and we have been a pioneer in introducing innovative cardiac imaging applications, the latest being CT-ECV."
  • "Presenting our enhanced MR cardiac application, we now offer additional features that capitalize on our extensive background in cardiac imaging, spanning decades.
  • By leveraging this expertise in cardiac imaging, we have developed a unified cardiac imaging solution on a singular platform for seamless workflow, enabling medical professionals to focus on enhanced diagnostic precision.."
    A newly redesigned user interface (UI) in REVORAS, provides a unified experience and streamlined workflow as well as enhanced contour extractions in MR cardiac imaging.

Global Cardiac Safety Services Market Projected to Reach USD 1,282 Million by 2028 at a CAGR of 11.6% - ResearchAndMarkets.com

Retrieved on: 
Monday, October 30, 2023
Biotechnology, Medical Devices, Health, Pharmaceutical, Cardiology, Drive, Growth, Ageing, Country, Incidence, Conditional sentence, Research, ChromeOS, Drug development, Genetic engineering, Cardiac imaging, Clinical trial, USD, Safety, Medication, Integration, Stand-alone, Medical device, Beauty salon, Pharmaceutical industry, Fine chemical, Dietary supplement

The global cardiac safety services market is on a robust growth trajectory, with projections indicating it will reach USD 1,282 million by 2028, up from USD 739 million in 2023, marking a remarkable CAGR of 11.6% during the forecast period from 2023 to 2028.

Key Points: 
  • The global cardiac safety services market is on a robust growth trajectory, with projections indicating it will reach USD 1,282 million by 2028, up from USD 739 million in 2023, marking a remarkable CAGR of 11.6% during the forecast period from 2023 to 2028.
  • Firstly, there has been a notable rise in the incidence of cardiovascular diseases, driving the demand for cardiac safety services.
  • Notably, the pharmaceutical and biopharmaceutical companies segment has been the largest end user of cardiac safety services during the forecast period.
  • Cardiac safety services play a pivotal role in ensuring the safety and efficacy of these drugs, thereby fulfilling regulatory requirements.

Jubilant Radiopharma and Cardiac Imaging, Inc. Announce Exclusive Partnership to Expand Access for Mobile Cardiac PET Offering

Retrieved on: 
Friday, September 29, 2023
Hospitals, Health, Radiology, Pharmaceutical, Cardiology, Learning, Cardiac imaging, ASNC, Partnership, Cardiac PET, CAD, PET, Westin Harbour Castle Hotel, Patient, Physician, Society, Heart, Hospital, Jubilant

Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.

Key Points: 
  • Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.
  • “This partnership with Cardiac Imaging allows unprecedented access of RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) to various types of facilities interested in performing cardiac PET,” said Sergio Calvo, President, Jubilant Radiopharma, Radiopharmaceuticals Division.
  • Cardiac Imaging, Inc.’s fixed site program is a comprehensive turnkey offering, enabling physicians to administer Cardiac PET in their own facilities.
  • Through these solutions, Cardiac Imaging, Inc. is advancing the field of cardiac PET and delivering premier cardiac care across the US.

HeartFlow, Inc. to Announce New Data on Diagnosing and Managing Coronary Artery Disease at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting

Retrieved on: 
Monday, July 24, 2023
Charleston Area Medical Center, CT scan, Cardiac imaging, University, Culture, MACC, FACC, Booth, CCTA, Research, Ability, SCCT, Plaque, Physician, Cardiology, University of British Columbia, AM, Coronary artery disease, Medical imaging, Doctor of Philosophy, Patient, MPH

MOUNTAIN VIEW, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the only non-invasive precision coronary care solution to provide both anatomic and physiologic insights, today announced that new data on HeartFlow Plaque Analysis and its RoadMapTM Analysis will be presented at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Boston, MA.

Key Points: 
  • MOUNTAIN VIEW, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the only non-invasive precision coronary care solution to provide both anatomic and physiologic insights, today announced that new data on HeartFlow Plaque Analysis and its RoadMapTM Analysis will be presented at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Boston, MA.
  • “The data being presented at SCCT are the latest findings in a robust body of evidence that show HeartFlow technologies help clinicians further improve diagnostic accuracy and clinical decision-making to ensure the right patients are getting the right care at the right time,” said Campbell Rogers, Chief Medical Officer of HeartFlow.
  • Featured speakers include Jonathon Leipsic, M.D., FSCCT, former president of SCCT; Jagat Narula, M.D., PhD, MACC, Executive Vice President and Chief Academic Officer at UTHealth Houston; Wesley O’Neal, M.D., MPH, FACC, Director, Cardiac CT and Nuclear Cardiology at Cone Health Heart & Vascular Center and Sarah Rinehart, M.D., FACC, FSCCT, Director of Cardiac Imaging, Director of Cardiology Fellowship at Charleston Area Medical Center.
  • Company representatives will also be available during the conference at Booth 207.

Dr. Scott D. Flamm, Former Section Head of Cardiovascular Imaging at Cleveland Clinic, Joins DocPanel

Retrieved on: 
Monday, May 1, 2023
San Francisco, Cardiac imaging, CT, Cleveland Clinic, Society, University, European Heart Journal: Cardiovascular Imaging, American Heart Association, American College of Cardiology, Head, Heart, University of California, San Francisco Fetal Treatment Center, FACC, Burlo Garofolo Pediatric Institute, MBA, Kellogg School, Radiology, MRI, Adrian Dixon, FAHA, Scientific Computing and Imaging Institute, Knowledge, American College, Northwestern University, Society for Cardiovascular Magnetic Resonance, Medical device

Formerly with Cleveland Clinic, Dr. Flamm served as Head of Cardiovascular Imaging with joint appointments in the Imaging Institute, Heart, Vascular, and Thoracic Institute, and the Pediatric Institute (2006-2023).

Key Points: 
  • Formerly with Cleveland Clinic, Dr. Flamm served as Head of Cardiovascular Imaging with joint appointments in the Imaging Institute, Heart, Vascular, and Thoracic Institute, and the Pediatric Institute (2006-2023).
  • "DocPanel and I share a mutual mission to make subspecialized cardiac imaging routine care that can be accessed by all," says Dr. Flamm.
  • Through the DocPanel platform, healthcare facilities can access Dr. Flamm for dedicated cardiothoracic imaging coverage, protocol assistance, and program development support.
  • Dr. Flamm completed fellowship training in Cardiovascular Imaging and MRI at the University of California San Francisco under Dr. Charles Higgins.

Global Cardiac Safety Services Market Report 2022 to 2027: Growth in Biosimilars and Biologics Markets Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Health, Cardiology, Blood pressure, Roe, Richmond Pharmacology, Cros, Clinical trial, LabCorp, Medication, SGS, USD, PPD, Inc., Stand-alone, Growth, Cardiac imaging, Conditional sentence, Drug discovery, Integration, Drug, Incidence, Medical device, Fine chemical, IQVIA, Arbutus Biopharma

The "Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The cardiac safety services market is projected to reach USD 1.0 Billion by 2027 from USD 0.6 Billion in 2022, at a CAGR of 11.2% during the forecast period.
  • Blood pressure monitoring is an essential part of cardiac safety services.
  • It accounted for the second largest market share of the cardiac safety services market.

MIM Software Inc. Receives Health Canada Approval for AI Auto-Contouring Software

Retrieved on: 
Tuesday, November 1, 2022
Nuclear medicine, Clinic, OH, Health, Contour, Hospital, Cardiac imaging, AI, Workflow, Health Canada, Multimedia, Environment, Software, Radiation therapy, Medical device, Medicine, Neuroimaging, Radiology

CLEVELAND, Nov. 1, 2022 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imagingsoftware, announced today it has received approval from Health Canada for its AI auto-contouring solution, Contour ProtgAI.

Key Points: 
  • CLEVELAND, Nov. 1, 2022 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imagingsoftware, announced today it has received approval from Health Canada for its AI auto-contouring solution, Contour ProtgAI.
  • Health Canada has approved Contour ProtgAI AI auto-contouring software, for quicker simulation to treatment times.
  • Contour ProtgAI seamlessly integrates into any department's workflow and can be rapidly implemented into virtually any environment via local deployment.
  • MIM Software sells its products globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies.

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

Retrieved on: 
Monday, August 22, 2022
Neoplasm, COVID-19, CEO, Technology, 3D, Cancer, XV, Research, OH, Alpha Sigma Tau, Brain, Xi, Solution, Software, Risk, Cardiac imaging, Data management, Radiation therapy, SEC, Nuclear medicine, U.S. Securities and Exchange Commission, Method, 100,000, Urology, GLOBE, Health, Pancreas, Nasdaq, Radiation, Annual report, MIM, Private Securities Litigation Reform Act, Vii, Alpha Tau Delta, Patient, Pharmaceutical industry, Medical imaging, Radiology, Tel Aviv University, Brachytherapy, Neuroimaging, Alpha

JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and MIM Software Inc. (MIM Software), a leading global provider of medical imaging software, announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy.

Key Points: 
  • JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and MIM Software Inc. (MIM Software), a leading global provider of medical imaging software, announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy.
  • Under the terms of the agreement, the parties will collaborate on the use of MIMs software suite, including MIM Symphony and MIMcloud, for development of new features and support for the Alpha DaRT across multiple potential indications, integration into all clinical trials involving the Alpha DaRT, and bundling the MIM software with the Alpha DaRT for future commercial sales in territories where the Alpha DaRT and MIMs software are both approved.
  • The MIM Symphony treatment planning software guides clinicians through an easy step-by-step process to place Alpha DaRT sources precisely and create a patient-personalized treatment plan.
  • Our collaboration with Alpha Tau is an excellent opportunity for MIM to impact radiotherapy and patient outcomes, said Andy Nelson, CEO of MIM Software.